Kerry Facility Expansion Helps Meet Demand for Lactose-Free Dairy

Why It Matters

The expansion secures a reliable lactase supply chain, enabling dairy companies to quickly respond to consumer demand for healthier, lactose‑free options and protect profit margins.

Key Takeaways

• Kerry expanded Carrigaline plant to boost lactase enzyme output.
• Capacity now supports processing over 2 million tonnes of milk annually.
• Expansion links Irish facility with German biotech centre and innovation hub.
• Faster scale‑up reduces bottlenecks for lactose‑free, sugar‑reduced dairy launches.
• Enhanced supply continuity helps dairy producers meet rising consumer demand.

Pulse Analysis

The global appetite for lactose‑free dairy has surged as consumers seek digestive comfort and lower sugar intake without sacrificing taste. According to market research, sales of lactose‑free milk, yogurt and cheese in Europe and North America grew double‑digit percentages in the past three years, driven by aging populations and heightened awareness of lactose intolerance. This trend forces dairy processors to secure reliable enzyme supplies quickly, lest they miss out on premium shelf space and brand loyalty. Consequently, manufacturers are looking for partners that can guarantee both volume and consistency.

Kerry’s newly expanded Carrigaline facility translates decades of enzyme engineering into industrial‑scale lactase production. By integrating its Irish plant with the biotech centre in Germany and a global innovation hub, the company can accelerate the transfer of laboratory breakthroughs to commercial batches. The upgrade lifts capacity to treat more than two million tonnes of milk each year, providing a buffer against supply shocks and enabling faster scale‑up for new formulations. For dairy producers, this means reduced lead times, lower risk of enzyme shortages, and the ability to launch lactose‑free or reduced‑sugar products with confidence.

The expanded enzyme output positions Kerry as a strategic supplier in a tightening dairy value chain. Consistent lactase availability helps processors avoid production bottlenecks, which can translate into higher margins and stronger brand differentiation. Moreover, the scalable platform opens opportunities for Kerry to apply its enzyme expertise to adjacent categories such as plant‑based milks and functional beverages. As regulatory pressure mounts for lower sugar content, the ability to swiftly adapt formulations will become a competitive moat, making reliable biotech partners indispensable for future growth.